---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031835"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:20:26.451072+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M

## Summary
- Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.
- Operating expenses down 43% to $5.5M; operating loss improved 81% to $1.4M.
- Acquired global rights to SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis.
- Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; partnered with Hello Alpha.
- Received $2.0M from Aditxt related to merger; targeting late 2024 close.

## SEC filing metadata
- accession: 0001493152-24-031835
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/0001493152-24-031835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031835
- JSON: https://secwatch.observer/filing/0001493152-24-031835.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.